6.63
price down icon3.77%   -0.26
after-market アフターアワーズ: 6.63
loading

Intellia Therapeutics Inc (NTLA) 最新ニュース

pulisher
04:56 AM

NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA - TradingView

04:56 AM
pulisher
12:00 PM

Intellia stock plunges to 52-week low of $6.49 amid market challenges - Investing.com

12:00 PM
pulisher
07:28 AM

Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN - Yahoo Finance

07:28 AM
pulisher
Apr 03, 2025

NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Expands Team: Strategic RSU Grants Worth 8,400 Shares to Attract Top Talent - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia begins phase 3 trial for gene-editing therapy - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Therapeutics Announces First Patient Dosed in the - GlobeNewswire

Apr 03, 2025
pulisher
Apr 03, 2025

Revolutionary One-Shot Gene Therapy Enters Final Testing Phase for Fatal Nerve Disease - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire

Apr 03, 2025
pulisher
Apr 02, 2025

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire

Apr 02, 2025
pulisher
Apr 02, 2025

NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com

Apr 02, 2025
pulisher
Apr 02, 2025

NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar

Apr 02, 2025
pulisher
Apr 01, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Long Term Trading Analysis for (NTLA) - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph

Apr 01, 2025
pulisher
Apr 01, 2025

ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView

Apr 01, 2025
pulisher
Apr 01, 2025

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6%Should You Sell? - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA - GlobeNewswire Inc.

Apr 01, 2025
pulisher
Apr 01, 2025

Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class ActionNTLA - PR Newswire

Apr 01, 2025
pulisher
Mar 31, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

8 Best Gene-Editing Stocks to Buy - Insider Monkey

Mar 31, 2025
pulisher
Mar 31, 2025

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

2025-03-31 | Intellia Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNTLA | NDAQ:NTLA | Press Release - Stockhouse

Mar 31, 2025
pulisher
Mar 31, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire

Mar 31, 2025
pulisher
Mar 31, 2025

Intellia Focuses on Pipeline Development Amid Stiff Competition - Yahoo Finance

Mar 31, 2025
pulisher
Mar 31, 2025

Contact The Gross Law Firm by April 14, 2025 Deadline to Join Class Action Against Intellia Therapeutics, Inc.(NTLA) - PR Newswire

Mar 31, 2025
pulisher
Mar 30, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire

Mar 30, 2025
pulisher
Mar 29, 2025

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph

Mar 29, 2025
pulisher
Mar 29, 2025

NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire

Mar 29, 2025
pulisher
Mar 28, 2025

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (NTLA) - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire

Mar 27, 2025
pulisher
Mar 27, 2025

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class ... - Bluefield Daily Telegraph

Mar 27, 2025
pulisher
Mar 27, 2025

Levi & Korsinsky Notifies Shareholders of Intellia - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - PR Newswire

Mar 27, 2025
pulisher
Mar 26, 2025

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review

Mar 26, 2025
pulisher
Mar 26, 2025

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 26, 2025

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia Therapeutics, Inc. Shareholders are Reminded of - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia Therapeutics, Inc. Shareholders are Reminded of the Lead Plaintiff Deadline – Contact Robbins LLP for Information on How to Lead the Class Action Against NTLA - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia stock plunges to 52-week low, hits $8.3 amid biotech rout - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

NTLA LAWSUIT ALERT: The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia gets FDA RMAT status for Regeneron-partnered gene editing drug - Seeking Alpha

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia Therapeutics' Nex-z Receives FDA Regenerative Medicine Advanced Therapy Designation - Nasdaq

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia gains FDA fast track for gene editing therapy - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Intellia's Gene Therapy Scores Major FDA Breakthrough: Single-Dose ATTR Heart Treatment Advances - StockTitan

Mar 26, 2025
pulisher
Mar 25, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edison, Elastic, Intellia, and ICON and Encourages Investors to Contact the Firm - TradingView

Mar 25, 2025
pulisher
Mar 24, 2025

2025-03-24 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. LawsuitNTLA | NDAQ:NTLA | Press Release - Stockhouse Publishing

Mar 24, 2025
pulisher
Mar 24, 2025

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors – ... - Bluefield Daily Telegraph

Mar 24, 2025
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
大文字化:     |  ボリューム (24 時間):